Epidemiology/Population Studies Milestones

Population Studies and Precision Medicine

Population Studies: Endophenotyping at-risk and resistant cohorts (Milestone 1.A)

Enable precision medicine research by supporting deep and longitudinal, molecular endophenotyping of existing and new, at-risk cohorts as well cohorts and/or individuals…
Population Studies: Quantify the exposome (Milestone 1.B)

Quantify the exposome in existing and new AD cohorts to gain a more precise measure of environmental exposure factors…
Population Studies: Diverse cohorts (Milestone 1.C)

Continue to establish new cohorts that include participants across diverse racial, ethnic and socioeconomic backgrounds…
Population Studies: State-of-the-art protocol (Milestone 1.D)

Develop state-of-the-art protocol for assessing dementia on large nationally representative samples…
Population Studies: Expand profiling efforts (Milestone 1.E)

Expand existing large scale, open-science molecular profiling efforts
Population Studies: Inclusion of non-AD cohorts (Milestone 1.F)

Support the inclusion of measures of AD-related phenotypes and environmental exposures in non-AD cohorts...
Population Studies: Longitudinal immunological profiling (Milestone 1.G)

Augment current and future human cohorts with more advanced, longitudinal immunological profiling (e.g. Cytof) to enable precision medicine research...
Population Studies: EHR access and integration (Milestone 1.H)

Enable access to electronic health records data and provide support for their integration with clinical and molecular data...
Health Equity: Identify risk factors across diverse populations (Milestone 1.I)

Assess epidemiology and mechanistic pathways of disparities in health burden of AD/ADRD.
Health Equity: Monitor trends of different ADRDs in diverse populations (Milestone 1.J)

Develop a system to monitor the magnitude and trends in health disparities in incidence of AD/ADRD.
LBD: Characterize LBD brain pathology (Milestone 1.K)

Characterize nervous system changes in LBD cohorts that have come to autopsy to identify disease-specific underlying mechanisms to guide biomarker and therapeutic approaches.
LBD: Understand LBD genetic, epigenetic, and environmental influences (Milestone 1.L)

Identify novel common and rare genetic variants, epigenetic changes, and environmental influences that impact the risk for and clinical features of LBD.
FTD Studies: Understand the natural history of FTD (Milestone 1.M)

Understand phenotypic heterogeneity and natural history in FTD.
TBI in AD/ADRD: Encourage research collaborations (Milestone 1.N)

Encourage crosstalk and interdisciplinary collaboration between TBI and dementia researchers.
TBI in AD/ADRD: Develop infrastructure for risk factor identification (Milestone 1.O)

Establish infrastructure to study TBI as a risk factor for AD/ADRD.
Population Studies: Exposome studies and health disparities (Milestone 1.P)

Expand current efforts to address health disparities research questions relevant to AD/ADRD by leveraging new and existing exposome AD/ADRD studies, including the impact of institutional and policy
Population Studies: Artificial intelligence (Milestone 1.Q)

Support research that uses Artificial Intelligence (AI) and deep learning approaches for discovery and translational research.
Population Studies: Polution and climate change (Milestone 1.R)

Support the research on the role of pollution and climate change on dementia risk.
Health Equity: Understand and reduce barriers to health equity (Milestone 1.S)

Assess the social, economic and structural impediments to equity in AD/ADRD assessment, diagnosis, and referrals, and impacts on health and economic outcomes.  
FTD: Studying FTD causes and risk factors in people (Milestone 1.T)

Understand FTD epidemiology and genetics in diverse populations, including how socioeconomic and ethnocultural status affects disease risk and manifestations.  
MED COVID-19: Understanding barriers to health equity (Milestone 1.U)

Impact of COVID-19 on AD/ADRD: Understanding barriers to health equity